1-6 of 6
Jeanette Lundin, MD
Close
Sort by
Journal Articles

Real-World Results on Ibrutinib in Relapsed/Refractory CLL: A 21-Month Follow-up of 95 Swedish Patients Treated in a Compassionate Use Program

Maria Winqvist, MSc, MD, Per-Ola Andersson, MD PhD, Anna Asklid, MD, Karin Karlsson, MD, Claes Karlsson, MD PhD, Birgitta Lauri, MD, Jeanette Lundin, MD PhD Assoc Prof, Mattias Mattsson, MD, Stefan Norin, MD PhD, Anna Bergendahl Sandstedt, MD, Lotta Hansson, Anders Österborg, MD PhD Prof.
Journal: Blood
Blood (2017) 130 (Supplement 1): 5353.
https://doi.org/10.1182/blood.V130.Suppl_1.5353.5353
Published: 2017
Journal Articles

Very Early Effects of Ibrutinib on Tumor and Immune Cells in Blood and Lymph Nodes in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Patients

Marzia Palma, MD PhD, Aleksandra Krstic, PhD, Anna Berglöf, PhD, Qing Wang, PhD, Emelie Blomberg, PhD, Stephan Meinke, PhD, Masood Kamali-Moghaddam, PhD, Qiujin Shen, PhD, Georg Jaremko, MD PhD, Jeanette Lundin, MD PhD, Eva Kimby, MD professor, Petter Höglund, MD PhD, Robert Månsson, PhD, Anders Österborg, MD PhD, Edvard Smith, PhD
Journal: Blood
Blood (2016) 128 (22): 3235.
https://doi.org/10.1182/blood.V128.22.3235.3235
Published: 2016
Journal Articles

In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study

Maria Winqvist, MD, Fariba Mozaffari, PhD, Marzia Palma, MD PhD, Sandra Eketorp Sylvan, MD PhD, Hakan Mellstedt, MD PhD, Anders Osterborg, MD PhD, Jeanette Lundin, MD PhD
Journal: Blood
Blood (2015) 126 (23): 4164.
https://doi.org/10.1182/blood.V126.23.4164.4164
Published: 2015
Journal Articles

Real-World Results on Ibrutinib in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Data from 97 Swedish Patients Treated in a Compassionate Use Program

Lotta Hansson, MD PhD, Maria Winqvist, MD, Anna Asklid, MD, P-O Andersson, MDPhD, Karin Karlsson, MD, Claes Karlsson, MDPhD, Birgitta Lauri, MD, Jeanette Lundin, MD PhD, Mattias Mattsson, MD, Stefan Norin, MDPhD, Anna Sandstedt, MD, Anders Österborg, MDPhD
Journal: Blood
Blood (2015) 126 (23): 1745.
https://doi.org/10.1182/blood.V126.23.1745.1745
Published: 2015
Journal Articles

A Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) - an Update

Jeanette Lundin, MD PhD, Steven T. Rosen, MD, Anders Österborg, MDPhD, Olga Frankfurt, MD, Jane N. Winter, MD, Alfred Rademaker, Jennifer Kreutzer, Elizabeth Bacon, Sonja Sönnert-Husa, Shuo Ma, MD PhD
Journal: Blood
Blood (2015) 126 (23): 1734.
https://doi.org/10.1182/blood.V126.23.1734.1734
Published: 2015
Journal Articles

a Phase 2 Study of Alemtuzumab-Ofatumumab (A+O) Combination in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)

Shuo Ma, MD PhD, Steven T. Rosen, MD, Olga Frankfurt, MD, Jane N. Winter, MD, Jennifer Kreutzer, Sonja Husa, Anders Österborg, Jeanette Lundin, MD
Journal: Blood
Blood (2014) 124 (21): 4686.
https://doi.org/10.1182/blood.V124.21.4686.4686
Published: 2014